血管性血友病因子对复发胶质瘤贝伐珠单抗治疗早期反应的预测价值
这项单中心、回顾性、纵向研究纳入49例接受贝伐珠单抗(每3周静脉10 mg/kg,单用或联合化疗)的复发胶质瘤患者,评估基线人口学、临床及实验室指标对3个月早期反应的预测价值。35%患者为反应者,其各采样时间点血管性血友病因子(VWF)水平均显著低于非反应者(p均<.02),多因素分析中基线VWF值是早期反应的唯一预测因素。
要点
- 35%的复发胶质瘤患者对贝伐珠单抗治疗3个月达到部分缓解,为反应者。
- 反应者各采样时间点VWF水平均显著低于非反应者(p均<.02)。
- 多因素分析中基线VWF值是贝伐珠单抗早期反应的唯一预测因素。
核心结论
- VWF抗原值可能是复发胶质瘤贝伐珠单抗治疗3个月早期反应的预测生物标志物。
研究设计与样本
- 单中心、回顾性、纵向研究,纳入49例接受贝伐珠单抗治疗的复发胶质瘤患者。
- 贝伐珠单抗按10 mg/kg静脉给药,每3周一次,单用或联合化疗。
- 在首次(基线)、第二次和第三次给药前采集血样。
主要发现
- 中位总随访8个月(范围1-73),中位总生存期8个月(95% CI 6-10),中位无进展生存期4个月(95% CI 3-5)。
- 35%患者为反应者,其各采样时间点VWF水平均显著低于非反应者(p均<.02)。
- 多因素分析中基线VWF值是贝伐珠单抗治疗早期反应的唯一预测因素。
- D-二聚体和凝血酶原片段1+2是总生存期的预测因素,卡氏功能状态评分是无进展生存期的预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bevacizumab (BV), a neutralizing monoclonal antibody against the vascular endothelial growth factor ligand, is recognized as a potent anti-angiogenic agent with antitumor activity. The aim of this single-center, retrospective, longitudinal study was to investigate the possible predictive value of baseline demographic, clinical and laboratory parameters for early 3-month response to BV therapy in patients with recurrent glioma. Forty-nine patients with recurrent glioma received BV at 10 mg/kg intravenously every 3 weeks alone or in association with chemotherapy were included in this study. Blood samples were collected from all patients before the first (baseline), the second and the third administration of BV. After 3 months of BV therapy, patients with partial response were defined as responders whereas patients with stable or progressive disease were defined as non-responders. The median overall follow-up was 8 months (range 1-73), the median overall survival (OS) was 8 months (95% CI 6-10) and the median progression free survival (PFS) was 4 months (95% CI 3-5). Thirty-five % of patients were responders and showed significantly lower von Willebrand factor (VWF) levels than non-responders at all sample times (p < .02 for all). Also, on multivariate analysis the baseline VWF value was the only predictor for an early response to BV therapy. Furthermore, D-dimer and prothrombin fragment 1+2 were predictive factors for OS while Karnofsky performance status resulted predictive for PFS. VWF antigen value is a possible predictive biomarker for an early 3-month response to BV therapy in recurrent glioma.
引用
- Pace A, Mandoj C, Antenucci A, et al. A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma. J Neurooncol. 2018. PMID: 29594657. doi:10.1007/s11060-018-2820-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。